RNase H Hot-Start Assays for Specific Oligonucleotide Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PCR assays face challenges with non-specific amplification, primer dimers, and carry-over contamination, which affect efficiency and specificity, and require costly hot-start DNA polymerases and additional enzymes like Uracil-N-Glycosylase.
Innovation Solution
Employing thermostable RNase H enzymes and modified oligonucleotides with cleavage domains, such as 2′-fluoro residues, to achieve specific primer extension and ligation reactions, reducing non-specific amplification and eliminating the need for reversibly inactivated DNA polymerases and ligases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If standard PCR protocols are used with primers hybridizing at lower temperatures, then primer extension reactions can proceed, but non-specific amplification and primer dimers form significantly
Solution Approach 1:
The primer is pre-modified with a blocking group at the 3'-end before the PCR reaction begins. This blocking group prevents premature primer extension at lower temperatures while allowing the primer to hybridize to the target sequence. The blocking group is subsequently removed by a specific enzyme (such as a phosphatase or glycosylase) only after proper hybridization has occurred, thereby enabling extension only under appropriate conditions and preventing non-specific amplification and primer dimer formation.
2Reliability
If hot-start protocols with reversibly inactivated DNA polymerase are used, then non-specific amplification is reduced, but the complexity and cost of the reaction mixture increases
Solution Approach 1:
The invention extracts the hot-start control mechanism from the DNA polymerase enzyme itself and transfers it to the primer molecule through the blocking group modification. This eliminates the need for reversibly inactivated polymerases, antibody-polymerase complexes, or other complex hot-start mechanisms. The simplified system uses only the modified primer and a specific removing enzyme, reducing reaction mixture complexity while maintaining amplification specificity.
3Measurement precision
If modified oligonucleotides with cleavage domains are used, then primer extension specificity is enhanced, but the manufacturing complexity of the oligonucleotides increases
Solution Approach 1:
The blocking group is placed at a specific local position (the 3'-end) of the oligonucleotide primer, rather than modifying the entire molecule. This localized modification allows the rest of the primer to maintain its standard sequence and structure, facilitating synthesis. The blocking group can be incorporated during standard oligonucleotide synthesis using modified phosphoramidites, and its removal is achieved through a specific enzymatic reaction that acts only on the blocking group, not the entire oligonucleotide, thereby balancing specificity enhancement with manufacturing feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the specificity and efficiency of PCR and related assays by preventing non-specific amplification and primer dimers, while reducing costs and complexity through the use of RNase H-mediated hot-start protocols.
Implementation Method 1
The RNase H enzyme will cleave the RNA component of RNA:DNA heteroduplexes
Implementation Method 2
a blocking group which prevents primer extension
Implementation Method 3
hybridizing the oligonucleotide to a complementary nucleic acid sequence
Data Source
AI summary
The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3′ end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein.


